Repression of E-cadherin by the polycomb group protein EZH2 in cancer

Q. Cao, J. Yu, S. M. Dhanasekaran, J. H. Kim, R. S. Mani, S. A. Tomlins, R. Mehra, B. Laxman, X. Cao, J. Yu, C. G. Kleer, S. Varambally, A. M. Chinnaiyan

Research output: Contribution to journalArticlepeer-review

484 Scopus citations


Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.

Original languageEnglish (US)
Pages (from-to)7274-7284
Number of pages11
Issue number58
StatePublished - Dec 11 2008


  • E-cadherin
  • Epigenetics
  • EZH2
  • Histone
  • Polycomb group protein

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Repression of E-cadherin by the polycomb group protein EZH2 in cancer'. Together they form a unique fingerprint.

Cite this